Letter: Optimizing Naloxegol Prescribing for Opioid-Induced Constipation

Sizar O , Gupta M , Genova R . Opioid induced constipation. Nih.gov. 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK493184/

Crockett SD , Greer KB , Heidelbaugh JJ , et al.; American Gastroenterological Association Institute Clinical Guidelines Committee. American Gastroenterological Association Institute Guideline on the Medical Management of Opioid-Induced Constipation. Gastroenterology, 2019; 156(1):218–226; doi: 10.1053/j.gastro.2018.07.016

Bruner HC , Atayee RS , Edmonds KP , Buckholz GT . Clinical utility of naloxegol in the treatment of opioid-induced constipation. J Pain Res, 2015; 8:289–294; doi: 10.2147/JPR.S61326

MOVANTIK (naloxegol) [package insert]. AstraZeneca Pharmaceuticals LP: Wilmington, DE; 2018.

Thomas J . Opioid-Induced Constipation: Clinical Guidance and Approved Therapies. U.S. Pharmacist, 2022; 47(1). Accessed June 16, 2025. https://www.uspharmacist.com/article/opioidinduced-constipation-clinical-guidance-and-approved-therapi

Savelloni J , Gunter H , Lee KC , et al. Risk of respiratory depression with opioids and concomitant gabapentinoids. J Pain Res, 2017 Nov 10; 10:2635–2641; doi: 10.2147/JPR.S144963. Erratum in: J Pain Res. 2018 Sep 17;11:1877; doi: 10.2147/JPR.S178586